Search Results
Jun 01, 2026, 03:47 ET Haier Launches Horizon Refrigerator in Vietnam, Setting New Standards for Freshness and Home Appliance Design
and produce clean ice quickly.Boasting a large capacity of up to 716L of space, adjustable shelves, and deep door bins, the refrigerator easily stores a full week's groceries for the whole family — including upright 1.5L bottles. Selected models feature AI Vision technology that automatically recognizes
More news about: Haier Group
Jun 01, 2026, 03:34 ET Scania launches battery-electric CrewCab for rescue vehicles
operations.SÖDERTÄLJE, Sweden, June 1, 2026 /PRNewswire/ -- The new battery-electric CP31L 4x2 is purpose-built to support demanding emergency operations while enabling transport operations with zero tailpipe emissions. Equipped with 356 kWh
More news about: Scania
Jun 01, 2026, 03:30 ET ENGWE Launches Y700ABE E-scooter in Germany for Long-Range Urban Commuting
has gained strong traction in the German market, while the L20 3.0 Pro was recognized with the iF Design Award for its product design.According to the company, future development will focus on products
More news about: ENGWE
Jun 01, 2026, 03:30 ET ENGWE bringt den E-Scooter Y700ABE in Deutschland für den städtischen Pendelverkehr mit großer Reichweite auf den Markt
dem deutschen Markt großen Anklang gefunden, während das L20 3.0 Pro für sein Produktdesign mit dem iF Design Award ausgezeichnet wurdeNach Angaben des Unternehmens wird sich die künftige Entwicklung
More news about: ENGWE
Jun 01, 2026, 03:05 ET MSA Safety Debuts Next-Generation Firefighter Technologies at Interschutz 2026
needs. A newly designed, helmet–integrated lighting option further enhances operational visibility. Key features include:L360™ lighting module, designed exclusively for the helmet to deliver balanced illumination during operations;A newly reimagined visor
More news about: MSA Safety
Jun 01, 2026, 03:05 ET MSA Safety debütiert auf der Interschutz 2026 mit Feuerwehrtechnologien der nächsten Generation
Beleuchtungsoption verbessert die Sichtverhältnisse im Einsatz zusätzlich. Zu den wichtigsten Merkmalen gehören:Das L360™ Beleuchtungsmodul, das speziell für den Helm entwickelt wurde, um während des Einsatzes eine ausgewogene Ausleuchtung zu gewährleisten;Ein
More news about: MSA Safety
Jun 01, 2026, 03:05 ET MSA Safety presenta tecnologías de última generación para bomberos en Interschutz 2026
el casco mejora aún más la visibilidad operativa. Entre sus características principales se incluyen:Módulo de iluminación L360™, diseñado exclusivamente para el casco, que proporciona una iluminación equilibrada durante las operaciones;Una visera rediseñada para
More news about: MSA Safety
Jun 01, 2026, 03:05 ET MSA Safety présente les technologies de nouvelle génération pour les pompiers à l'occasion du salon Interschutz 2026
intégrée au casque améliore encore la visibilité opérationnelle. Principales caractéristiques :Le module d'éclairage L360™, conçu exclusivement pour le casque afin de fournir un éclairage équilibré pendant les opérations.Une visière nouvellement repensée,
More news about: MSA Safety
Jun 01, 2026, 03:04 ET China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
requiring mechanical ventilation: a pooled post-hoc analysis of data from phase 2 and phase 3 trials. Ann Intensive Care. 2024;7.8(IF).Qin LL, Ren L, Wan SL, et al. Design, synthesis, and evaluation of novel 2,6-disubstituted phenol derivatives as general anesthetics. J Med Chem. 2017;7.3(IF).Liang
More news about: Haisco
Jun 01, 2026, 01:57 ET VINFAST AND AUTOBRAINS LAUNCH FIRST AGENTIC AI L4 PROGRAM FOR SOUTHEAST ASIA WITH NVIDIA
multimedia:https://www.prnewswire.com/news-releases/vinfast-and-autobrains-launch-first-agentic-ai-l4-program-for-southeast-asia-with-nvidia-302786788.htmlSOURCE
More news about: VinFast
Jun 01, 2026, 01:35 ET Supermicro Introduces DCBBS Blueprints for NVIDIA Vera Rubin NVL72 and NVIDIA HGX™ Rubin NVL8, Built to Scale from 5MW to 1GW as an End-to-End Total Solution
cabling within each rack. Supermicro verifies functionality with a testing process that exceeds industry standards, extending to system-level (L10) and cluster-level (L11) multi-node tests. The Supermicro dedicated team manages the logistics of site-level components such as CDUs, cooling towers, and power infrastructure,
More news about: Super Micro Computer, Inc.
Jun 01, 2026, 00:00 ET Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
disease; a novel PD-1/VEGF bispecific antibody in Phase 2 trials, being evaluated in combination with a TROP2 ADC; and a B7-H3 ADC in Phase 3 trial for 2L SCLC —both ADCs with strong best-in-class potential.Forward-Looking StatementsThis press release contains forward-looking statements
More news about: Minghui Pharmaceutical
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
across four groups:(1) Group 1 (≥2L NSCLC monotherapy), n=57: CS2009 was dosed at 10–45 mg/kg, once every 3 weeks (Q3W);(2) Group 2 (2/3L NSCLC combination therapy), n=9: CS2009 was dosed at 20 or 30 mg/kg, Q3W plus docetaxel;(3) Group 3 (1L NSCLC monotherapy ), n=23: CS2009 was
More news about: CStone Pharmaceuticals
May 31, 2026, 20:15 ET Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
of 5 cycles (range, 4-11) of 1L chemotherapy before satri-cel infusion, with only 1 patient achieved partial response (PR) after 1L therapy. Overall, the efficacy of 1L therapy was poor.As of October 18, 2025, the median follow-up of the 5 patients from initial 1L therapy was 54.6 months. Among
More news about: CARsgen Therapeutics
May 31, 2026, 20:00 ET 德昇濟醫藥在ASCO 2026公布Elisrasib（D3S-001）一線治療數據；新一代KRAS G12C抑制劑在初治NSCLC中展現裡程碑式療效
Elisrasib單藥在KRAS G12C突變晚期NSCLC一線治療中實現78.0%的客觀緩解率（ORR），中位無進展生存期（PFS）為12.4個月（n=41），且在各PD-L1表達水平人群中療效一致Elisrasib聯合帕博利珠單抗在一線治療中實現81.3%的ORR（n=48），12個月PFS率達53.7%上海2026年6月1日 /美通社/ -- 德昇濟醫藥，一家致力於創新腫瘤療法開發的全球臨床階段生物技術公司，今日宣布其新一代KRAS
More news about: 德昇濟醫藥（D3 Bio）
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
efficacy-evaluable patients, an ORR 81.3% was observed across all PD-L1 expression levels, with ORR of 70.6% in patients with PD-L1 TPS <1% (N=17), 72.7% in patients with PD-L1 TPS of 1% to 49% (N=11), and 95.0% in patients with PD-L1 TPS ≥50% (N=20), respectively. The overall DCR was 97.9%. The median
More news about: D3 Bio
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
65.2% patients had NSCLC tumors demonstrating PD-L1 TPS < 1% and 34.8% had TPS 1–49%.In the IBI363 3→1.5 mg/kg Dose Group, ORR Exceeded 80% in the First-line Treatment of NSCLC, Across Histologies and Particularly in PD-L1 Negative or Low ExpressionPreliminary
More news about: Innovent Biologics
May 31, 2026, 20:00 ET ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability
More news about: ImmVira Group
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Protein)IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and selectively activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to
More news about: Innovent Biologics
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at American Society of Clinical Oncology (ASCO) 2026.
More news about: TiumBio
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
notice.References 1. Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy,
More news about: Servier Pharmaceuticals
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
subgroupsOS benefit with ivonescimab was observed consistently regardless of PD-L1 expression status: HR=0.68 in the PD-L1 TPS ≥1% subgroup and HR=0.64 in the TPS <1% subgroup; HR=0.67 in the PD-L1 TPS 1–49% subgroup and HR=0.64 in the TPS ≥50% subgroup.The OS benefit was also consistent
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose
More news about: Johnson & Johnson
May 31, 2026, 00:13 ET Huawei è stata riconosciuta come Leader nel Gartner® Magic Quadrant™ 2026 dedicato alle infrastrutture LAN aziendali cablate e wireless per il quarto anno consecutivo
end-to-end e osservabilità dell'esperienza. Grazie a un processo decisionale globale basato su IA e alla localizzazione dei guasti a livello di minuti, l'80% dei problemi wireless viene risolto automaticamente.Guardando al futuro, Huawei continuerà a innovare partendo dalle esigenze dei clienti e ad
More news about: Huawei
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
other study reported results for golidocitinib, a JAK1-selective inhibitor, combined with an anti-PD-1 antibody as a first-line treatment for PD-L1-positive, advanced NSCLC without driver mutations.
More news about: Dizal Pharmaceutical